IMMUNOVANT INC (IMVT) Stock Analyst Ratings
USA - NASDAQ:IMVT - US45258J1025 - Common Stock
22.96 USD
-0.48 (-2.05%)
ChartMill assigns a Buy % Consensus number of 82% to IMVT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 38.6. This target is 68.13% above the current price.
IMVT was analyzed by 23 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about IMVT.
In the previous month the buy percentage consensus was at a similar level.
IMVT was analyzed by 23 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-14 | Truist Securities | Initiate | Hold |
| 2025-09-30 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-12 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-12 | B of A Securities | Maintains | Buy -> Buy |
| 2025-07-28 | UBS | Maintains | Neutral -> Neutral |
| 2025-04-22 | UBS | Downgrade | Buy -> Neutral |
| 2025-03-20 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-03-20 | B of A Securities | Maintains | Buy -> Buy |
| 2025-03-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-10 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-02-10 | Guggenheim | Maintains | Buy -> Buy |
| 2025-02-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-15 | B of A Securities | Maintains | Buy -> Buy |
| 2025-01-03 | Wolfe Research | Downgrade | Outperform -> Peer Perform |
| 2024-12-19 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-10 | Raymond James | Reiterate | Outperform |
| 2024-10-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-09-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-09 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-08-13 | UBS | Maintains | Buy -> Buy |
| 2024-08-08 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-08-07 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-06-20 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-06-18 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-06-03 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-05-30 | Cantor Fitzgerald | Reiterate | Overweight |
IMMUNOVANT INC / IMVT FAQ
What do analysts expect the price target to be for IMMUNOVANT INC (IMVT)?
23 analysts have analysed IMVT and the average price target is 38.6 USD. This implies a price increase of 68.13% is expected in the next year compared to the current price of 22.96.
Can you provide the consensus rating for IMMUNOVANT INC stock?
The consensus rating for IMMUNOVANT INC (IMVT) is 81.7391 / 100 . This indicates that analysts generally have a positive outlook on the stock.